FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2318668462> ?p ?o ?g. }

• W2318668462 endingPage "948" @default.
• W2318668462 startingPage "948.1" @default.
• W2318668462 abstract "<h3>Background</h3> RA patients typically present with pain and morning stiffness (MS) in addition to joint swelling and tenderness. Nocturnal inflammatory cytokines are assumed to be associated with MS. DR prednisone given at bedtime has previously shown significant absolute and relative reduction in MS and early morning cytokines compared to both conventional (IR) prednisone and placebo in well controlled studies.(1,2) Studies of categorical and comparative MS responses to DR and IR prednisone are lacking. <h3>Objectives</h3> In this new analysis of Phase 3 study data, we completed a time-to-event analysis of morning stiffness <h3>Methods</h3> CAPRA-1, a 12-week, double-blind, controlled study, randomized patients to IR-prednisone taken in the morning or DR-prednisone taken once daily at bedtime (eg, 10pm) in addition to standard DMARD treatment.(1) In the following open label phase (2), patients previously receiving IR prednisone (N=110) were then switched to DR-prednisone and followed at 3, 6, and 9 months.(2) Patients previously on DR-prednisone (N=97) continued on therapy. Patients completed diary entries at least 7 days prior to each visit including waking time, stiffness (yes/no), time of resolution and intensity of pain (VAS) during the day. In a novel analysis, all diary entries±4 weeks of each scheduled visit were analyzed over 1 year for threshold response (see Figure 1). Weekly data was available during the DB study. Chi-square tests for category treatment differences were completed at end of DB and months 6, 9, and 12. Kaplan-Meier estimates and p-values were computed using a Cox proportional model. The response categories were not mutually exclusive <h3>Results</h3> The DR prednisone arm had statistically significantly more responders in each of the 3 MS response categories at the end of the DB period as compared to IR prednisone (p≤0.05). DR prednisone had higher percentages of responders in the 3 response categories at each 12 week evaluation. The separation started after 1 week of therapy. Of those who had responses in the DB study, it took longer for the IR prednisone group to reach the same level of response. The IR prednisone group, when switched to DR prednisone, had comparable responses in all categories within 3 months and significantly shorter time to response when compared to patients already receiving DR prednisone (p≤0.008) <h3>Conclusions</h3> DR prednisone, as compared to IR prednisone, produces significantly higher MS response rates as defined by 25/50/75% improvement thresholds. The time to reach these thresholds is quicker with DR prednisone and patients switched to DR prednisone from IR prednisone quickly “catch up” and manifest comparable responses. Patients treated with DR prednisone maintained their response with no evidence of tachyphylaxis up to 1 year <h3>References</h3> Buttgereit, et. al. Lancet 2008;371:205-214. Buttgereit, et. al. Ann Rheum Dis 2010;69:127-1280 <h3>Disclosure of Interest</h3> F. Buttgereit Consultant for: Horizon Pharma, Inc, J. Kent Employee of: Horizon Pharma, Inc, R. Holt Consultant for: Horizon Pharma, Inc, A. Grahn Employee of: Horizon Pharma, Inc, P. Rice Consultant for: Horizon Pharma, Inc, R. Alten Consultant for: Horizon Pharma, Inc, Y. Yazici Consultant for: Horizon Pharma, Inc <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.1467" @default.
• W2318668462 created "2016-06-24" @default.
• W2318668462 creator A5004250800 @default.
• W2318668462 creator A5017975302 @default.
• W2318668462 creator A5020895246 @default.
• W2318668462 creator A5031970634 @default.
• W2318668462 creator A5035404908 @default.
• W2318668462 creator A5058094909 @default.
• W2318668462 creator A5060526475 @default.
• W2318668462 date "2014-06-01" @default.
• W2318668462 modified "2023-10-16" @default.
• W2318668462 title "AB0426 Time to Event Analysis of Patient Reported Morning Stiffness Where Delayed-Release (DR) Prednisone Was Compared To, and Replaced, Immediate Release Prednisone in Rheumatoid Arthritis (RA) Patients Receiving DMARDS over 1 Year" @default.
• W2318668462 doi "https://doi.org/10.1136/annrheumdis-2014-eular.1467" @default.
• W2318668462 hasPublicationYear "2014" @default.
• W2318668462 type Work @default.
• W2318668462 sameAs 2318668462 @default.
• W2318668462 citedByCount "0" @default.
• W2318668462 crossrefType "journal-article" @default.
• W2318668462 hasAuthorship W2318668462A5004250800 @default.
• W2318668462 hasAuthorship W2318668462A5017975302 @default.
• W2318668462 hasAuthorship W2318668462A5020895246 @default.
• W2318668462 hasAuthorship W2318668462A5031970634 @default.
• W2318668462 hasAuthorship W2318668462A5035404908 @default.
• W2318668462 hasAuthorship W2318668462A5058094909 @default.
• W2318668462 hasAuthorship W2318668462A5060526475 @default.
• W2318668462 hasConcept C126322002 @default.
• W2318668462 hasConcept C142724271 @default.
• W2318668462 hasConcept C19720800 @default.
• W2318668462 hasConcept C204787440 @default.
• W2318668462 hasConcept C27081682 @default.
• W2318668462 hasConcept C2777575956 @default.
• W2318668462 hasConcept C2778537899 @default.
• W2318668462 hasConcept C2778720950 @default.
• W2318668462 hasConcept C71924100 @default.
• W2318668462 hasConceptScore W2318668462C126322002 @default.
• W2318668462 hasConceptScore W2318668462C142724271 @default.
• W2318668462 hasConceptScore W2318668462C19720800 @default.
• W2318668462 hasConceptScore W2318668462C204787440 @default.
• W2318668462 hasConceptScore W2318668462C27081682 @default.
• W2318668462 hasConceptScore W2318668462C2777575956 @default.
• W2318668462 hasConceptScore W2318668462C2778537899 @default.
• W2318668462 hasConceptScore W2318668462C2778720950 @default.
• W2318668462 hasConceptScore W2318668462C71924100 @default.
• W2318668462 hasIssue "Suppl 2" @default.
• W2318668462 hasLocation W23186684621 @default.
• W2318668462 hasOpenAccess W2318668462 @default.
• W2318668462 hasPrimaryLocation W23186684621 @default.
• W2318668462 hasRelatedWork W1959736672 @default.
• W2318668462 hasRelatedWork W1981896044 @default.
• W2318668462 hasRelatedWork W2073942396 @default.
• W2318668462 hasRelatedWork W2399720854 @default.
• W2318668462 hasRelatedWork W2907565595 @default.
• W2318668462 hasRelatedWork W3013328883 @default.
• W2318668462 hasRelatedWork W3088409979 @default.
• W2318668462 hasRelatedWork W3131469134 @default.
• W2318668462 hasRelatedWork W3202397728 @default.
• W2318668462 hasRelatedWork W4223945581 @default.
• W2318668462 hasVolume "73" @default.
• W2318668462 isParatext "false" @default.
• W2318668462 isRetracted "false" @default.
• W2318668462 magId "2318668462" @default.
• W2318668462 workType "article" @default.